苏沃雷生：修订间差异

**苏沃雷生**
臨床資料
其他名稱	MK-4305; MK4305
AHFS/Drugs.com	Monograph
MedlinePlus	a614046
核准狀況	美 DailyMed: Suvorexant;
依賴性	低
成癮性	低
给药途径	口服
藥物類別（英语：Drug class）	食欲素受体激动剂; 催眠药; 镇定剂
ATC碼	N05CM19 (WHO) ;
法律規範狀態
法律規範	澳：限医生处方（S4）; 中：第二类精神药品; 美：附表IV;
识别信息
	IUPAC命名法 [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone; ;
CAS号	1030377-33-3
PubChem CID	24965990;
IUPHAR/BPS	2890;
DrugBank	DB09034 ;
ChemSpider	24662178 ;
UNII	081L192FO9;
KEGG	D10082 ;
ChEBI	CHEBI:82698;
ChEMBL	ChEMBL1083659 ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID90145616 ;
ECHA InfoCard	100.210.546
化学信息
化学式	C23H23ClN6O2
摩尔质量	450.93 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;
	InChI InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1 ; Key:JYTNQNCOQXFQPK-MRXNPFEDSA-N ;

下一版本→

删除的内容添加的内容

可视化wikitext

行内

2023年7月23日 (日) 12:15的版本

苏沃雷生，品牌名Belsomra，是一种食欲素受体拮抗剂，被用于治疗失眠症，主要用于入睡或睡眠维持困难的成年患者的治疗。^[1]^[2]^[3]苏沃雷生具有加速入睡、延长睡眠时间、减少半夜醒来次数以及提高睡眠质量的作用。^[1]^[2]^[4]其药效中等，^[5]与其他食欲素受体拮抗剂类似，但低于苯二氮卓类药物与非苯二氮卓类药物。^[6]苏沃雷生的给药方式为口服给药。^[1]^[2]^[3]^[7]

苏沃雷生的副作用包括嗜睡、头晕、白天嗜睡和镇静、头痛、头晕、梦境异常、口干和次日驾驶能力受损。^[1]^[4]^[8]偶见睡眠麻痹，做梦异常与梦游等复杂睡眠行为与出现自杀意念。^[1]^[2]^[8]服用这种药物似乎不会产生明显的药物耐受性、药物依赖、戒断症状和反弹现象。^[1]^[9]^[10]苏沃雷生是一种双重食欲素受体激动剂（DORA），选择性拮抗食欲素1型受体（Ox1R）和食欲素2型受体（Ox2R）。^[2]该药物的达峰时间为2至3小时，清除半衰期为12小时。^[1]^[2]与苯二氮卓类药物与非苯二氮卓类药物不同的是，苏沃雷生并不会与 GABA 受体发生相互作用，而是通过其特殊的药理学机制发挥作用。^[2]^[11]

^ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 ^1.6 DailyMed - BELSOMRA- suvorexant tablet, film coated. dailymed.nlm.nih.gov. [2023-07-23].
^ ^2.0 ^2.1 ^2.2 ^2.3 ^2.4 ^2.5 ^2.6 Jacobson, Laura H.; Callander, Gabrielle E.; Hoyer, Daniel. Suvorexant for the treatment of insomnia. Expert Review of Clinical Pharmacology. 2014-11, 7 (6). ISSN 1751-2441. PMID 25318834. doi:10.1586/17512433.2014.966813.
^ ^3.0 ^3.1 苏沃雷生[精二]_其他镇静催眠药_镇静药与催眠药_作用于神经系统的药物_湖南药事服务网. www.hnysfww.com. [2023-07-23].
^ ^4.0 ^4.1 Kuriyama, Akira; Tabata, Hiromitsu. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Sleep Medicine Reviews. 2017-10, 35. ISSN 1532-2955. PMID 28365447. doi:10.1016/j.smrv.2016.09.004.
^ Table 1: The Single Nucleotide Polymorphisms in cathepsin B protein mined from literature (PMID: 16492714).. dx.doi.org. [2023-07-23].
^ De Crescenzo, Franco; D'Alò, Gian Loreto; Ostinelli, Edoardo G; Ciabattini, Marco; Di Franco, Valeria; Watanabe, Norio; Kurtulmus, Ayse; Tomlinson, Anneka; Mitrova, Zuzana; Foti, Francesca; Del Giovane, Cinzia. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. The Lancet. 2022-07, 400 (10347). doi:10.1016/S0140-6736(22)00878-9 （英语）.
^ https://www.facebook.com/Drugscom. Generic Belsomra Availability. Drugs.com. [2023-07-23] （英语）.
^ ^8.0 ^8.1 Sutton, Eliza. Profile of suvorexant in the management of insomnia. Drug Design, Development and Therapy. 2015-11. ISSN 1177-8881. PMC 4651361 . PMID 26648692. doi:10.2147/DDDT.S73224 （英语）. 引文格式1维护：PMC格式 (link)
^ Keks, Nicholas A.; Hope, Judy; Keogh, Simone. Suvorexant: scientifically interesting, utility uncertain. Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists. 2017-12, 25 (6). ISSN 1440-1665. PMID 28994603. doi:10.1177/1039856217734677.
^ Muehlan, Clemens; Vaillant, Cedric; Zenklusen, Isabelle; Kraehenbuehl, Stephan; Dingemanse, Jasper. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology. 2020-11-01, 16 (11). ISSN 1742-5255. doi:10.1080/17425255.2020.1817380 （英语）.
^ Atkin, Tobias; Comai, Stefano; Gobbi, Gabriella. Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. Pharmacological Reviews. 2018-04, 70 (2). ISSN 1521-0081. PMID 29487083. doi:10.1124/pr.117.014381.
^ cite web | title=Prescription medicines: registration of new chemical entities in Australia, 2016 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 |}
^ Prescription medicines: registration of new chemical entities in Australia, 2016. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023].

[:0-1] 1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 ^1.6 DailyMed - BELSOMRA- suvorexant tablet, film coated. dailymed.nlm.nih.gov. [2023-07-23].

[:1-2] 2.0 ^2.1 ^2.2 ^2.3 ^2.4 ^2.5 ^2.6 Jacobson, Laura H.; Callander, Gabrielle E.; Hoyer, Daniel. Suvorexant for the treatment of insomnia. Expert Review of Clinical Pharmacology. 2014-11, 7 (6). ISSN 1751-2441. PMID 25318834. doi:10.1586/17512433.2014.966813.

[:2-3] 3.0 ^3.1 苏沃雷生[精二]_其他镇静催眠药_镇静药与催眠药_作用于神经系统的药物_湖南药事服务网. www.hnysfww.com. [2023-07-23].

[:3-4] 4.0 ^4.1 Kuriyama, Akira; Tabata, Hiromitsu. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Sleep Medicine Reviews. 2017-10, 35. ISSN 1532-2955. PMID 28365447. doi:10.1016/j.smrv.2016.09.004.

[5] Table 1: The Single Nucleotide Polymorphisms in cathepsin B protein mined from literature (PMID: 16492714).. dx.doi.org. [2023-07-23].

[6] De Crescenzo, Franco; D'Alò, Gian Loreto; Ostinelli, Edoardo G; Ciabattini, Marco; Di Franco, Valeria; Watanabe, Norio; Kurtulmus, Ayse; Tomlinson, Anneka; Mitrova, Zuzana; Foti, Francesca; Del Giovane, Cinzia. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. The Lancet. 2022-07, 400 (10347). doi:10.1016/S0140-6736(22)00878-9 （英语）.

[7] ttps://www.facebook.com/Drugscom. Generic Belsomra Availability. Drugs.com. [2023-07-23] （英语）.

[:4-8] 8.0 ^8.1 Sutton, Eliza. Profile of suvorexant in the management of insomnia. Drug Design, Development and Therapy. 2015-11. ISSN 1177-8881. PMC 4651361 . PMID 26648692. doi:10.2147/DDDT.S73224 （英语）. 引文格式1维护：PMC格式 (link)

[9] Keks, Nicholas A.; Hope, Judy; Keogh, Simone. Suvorexant: scientifically interesting, utility uncertain. Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists. 2017-12, 25 (6). ISSN 1440-1665. PMID 28994603. doi:10.1177/1039856217734677.

[10] Muehlan, Clemens; Vaillant, Cedric; Zenklusen, Isabelle; Kraehenbuehl, Stephan; Dingemanse, Jasper. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology. 2020-11-01, 16 (11). ISSN 1742-5255. doi:10.1080/17425255.2020.1817380 （英语）.

[11] Atkin, Tobias; Comai, Stefano; Gobbi, Gabriella. Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. Pharmacological Reviews. 2018-04, 70 (2). ISSN 1521-0081. PMID 29487083. doi:10.1124/pr.117.014381.

[12] te web | title=Prescription medicines: registration of new chemical entities in Australia, 2016 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 |}

[13] Prescription medicines: registration of new chemical entities in Australia, 2016. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023].

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[13]

[12]